Meeting
2022 ASCO Annual Meeting
Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).
Authors
Camila Bragança Xavier
Hospital Sírio-Libanês, São Paulo, Brazil
Camila Bragança Xavier , Gabriela Guardia , Carlos Diego Holanda Lopes , Beatriz Mendes Awni , Eduardo Felicio Campos , João Pedro Alves , Anamaria Aranha Camargo , Pedro Alexandre Favoretto Galante , Denis L. Jardim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2632)
DOI
10.1200/JCO.2022.40.16_suppl.2632
Abstract #
2632
Poster Bd #
287
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2021 ASCO Annual Meeting
Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.
First Author: Chul Kim
Poster
2017 ASCO Annual Meeting
Profiling circulating tumor (ct)DNA mutations after panitumumab treatment in patients with refractory metastatic colorectal cancer (mCRC) from the phase III ASPECCT study.
First Author: Michael Boedigheimer
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates